Mechanism of action
Atomoxetine selectively inhibits the presynaptic norepinephrine transporter (NET) with minimal affinity for other neurotransmitter transporters or receptors. By blocking norepinephrine reuptake, particularly in the prefrontal cortex, atomoxetine increases extracellular norepinephrine concentrations in regions critical for attention, impulse control, and executive function.
Unlike stimulant medications (methylphenidate, amphetamines), atomoxetine does not directly increase dopamine in the nucleus accumbens or striatum, which explains its lack of abuse potential and non-controlled status. The therapeutic effect is thought to arise from enhanced noradrenergic signaling in prefrontal and frontal cortical regions that modulate attention and behavioral inhibition.
Atomoxetine has minimal effects on serotonin or dopamine transporters and does not act as a monoamine oxidase inhibitor. The selectivity for norepinephrine reuptake distinguishes it from serotonin-norepinephrine reuptake inhibitors (SNRIs) used for depression or anxiety, which have more balanced serotonin and norepinephrine effects.
- Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI), not a stimulant, and is not a controlled substance.
- Black box warning: increased risk of suicidal ideation in children and adolescents with ADHD.
- Contraindicated with MAOIs (within 14 days) and in narrow-angle glaucoma or pheochromocytoma.
- Metabolized by CYP2D6; poor metabolizers have 10-fold higher drug levels and prolonged half-life.
- Onset of therapeutic effect takes 2-4 weeks, unlike stimulants which work within hours.
- Can cause hepatotoxicity (rare); discontinue if jaundice or elevated liver enzymes occur.
- Preferred in ADHD patients with comorbid tics, anxiety, or substance use disorder history.
- Increases heart rate and blood pressure; monitor cardiovascular parameters regularly.
Indications
Atomoxetine is FDA-approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients (6 years and older), adolescents, and adults. It is considered a first-line non-stimulant option for ADHD management.
Primary indication:
- Attention-deficit/hyperactivity disorder (ADHD)
Clinical scenarios favoring atomoxetine:
- Patients with comorbid anxiety disorders
- Patients with tic disorders or Tourette syndrome (stimulants may worsen tics)
- Individuals with substance use disorder history or high abuse risk
- Patients who cannot tolerate stimulant side effects (insomnia, appetite suppression)
- Situations where 24-hour symptom control is desired (atomoxetine has once-daily dosing)
Atomoxetine may be used as monotherapy or when stimulant medications are contraindicated, ineffective, or poorly tolerated. Therapeutic effects typically emerge after 2-4 weeks of treatment, unlike stimulants which work within hours.
Pharmacokinetics
Absorption: Atomoxetine is rapidly absorbed after oral administration with peak plasma concentrations occurring approximately 1-2 hours post-dose. Food does not significantly affect absorption, though it may slow the rate.
Distribution: Atomoxetine is highly protein-bound (approximately 98%) and has a volume of distribution of 0.85 L/kg, indicating distribution throughout body water.
Metabolism: Atomoxetine undergoes extensive hepatic metabolism primarily via CYP2D6. It is hydroxylated to 4-hydroxyatomoxetine (equipotent but rapidly glucuronidated) and N-desmethylatomoxetine (less active). Approximately 7-10% of the population are CYP2D6 poor metabolizers, resulting in 10-fold higher atomoxetine plasma concentrations and prolonged half-life (up to 24 hours vs 5 hours in extensive metabolizers).
Excretion: Metabolites are excreted primarily in urine (over 80%). Less than 3% of a dose is excreted as unchanged drug.
Half-life: The elimination half-life is approximately 5 hours in extensive metabolizers and 21-24 hours in poor metabolizers. Once-daily or twice-daily dosing is appropriate depending on metabolizer status and clinical response. Dosing adjustments follow the product label.
Adverse effects
Black box warning: Atomoxetine carries a black box warning for increased risk of suicidal ideation in children and adolescents. Close monitoring is required, especially during initial treatment and dose changes.
Common adverse effects:
- Gastrointestinal: Nausea, vomiting, decreased appetite, abdominal pain, constipation
- Cardiovascular: Increased heart rate, elevated blood pressure (monitor BP and HR regularly)
- Psychiatric: Mood swings, irritability, insomnia, anxiety
- Other: Dry mouth, dizziness, fatigue, headache, sexual dysfunction (decreased libido, erectile dysfunction)
Serious adverse effects:
- Hepatotoxicity: Rare but severe liver injury can occur; discontinue if jaundice or elevated liver enzymes develop
- Cardiovascular: Orthostatic hypotension, syncope, tachycardia, palpitations, QT prolongation (less common)
- Growth suppression: Monitor height and weight in pediatric patients; growth velocity may decrease
- Urinary retention: Particularly in patients with urinary outflow obstruction
- Priapism: Rare but reported; requires immediate medical attention
- Aggression and hostility: New or worsening aggressive behavior, especially in pediatric patients
Withdrawal: Atomoxetine can be discontinued without tapering, though abrupt discontinuation may cause transient rebound ADHD symptoms in some patients.
Patients should be monitored for emergence of suicidal thoughts, unusual behavior changes, cardiovascular symptoms, and hepatic dysfunction throughout treatment.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to atomoxetine or any component
- Use within 14 days of monoamine oxidase inhibitor (MAOI) therapy (risk of hypertensive crisis)
- Narrow-angle glaucoma (increased risk of mydriasis and angle closure)
- Pheochromocytoma (risk of hypertensive crisis)
Warnings and precautions:
Cardiovascular: Atomoxetine can increase heart rate (average 5-10 bpm) and blood pressure (2-4 mmHg). Baseline cardiovascular assessment is recommended. Use with caution in patients with hypertension, tachycardia, or structural cardiac abnormalities. Sudden cardiac death has been reported in patients with serious cardiac conditions.
Psychiatric: Monitor for emergence or worsening of anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, or suicidal ideation, especially in children and adolescents. Patients with comorbid bipolar disorder may experience manic or mixed episodes.
Hepatic impairment: Dose adjustment is necessary in moderate to severe hepatic impairment. Discontinue atomoxetine in patients with jaundice or laboratory evidence of liver injury.
CYP2D6 poor metabolizers: Poor metabolizers achieve higher plasma concentrations; consider dose reduction if adverse effects emerge.
Pregnancy and lactation: Atomoxetine is pregnancy category C. Use during pregnancy only if benefits outweigh risks. Atomoxetine is excreted in breast milk; consider risks to the nursing infant.
Growth and development: Monitor height and weight in pediatric patients. Consider treatment interruption if growth is suppressed.
Drug interactions
CYP2D6 inhibitors: Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine, bupropion) increase atomoxetine plasma concentrations significantly. Dose reduction may be necessary to avoid toxicity.
MAOIs: Concomitant use with MAOIs (phenelzine, tranylcypromine, selegiline) or within 14 days is contraindicated due to risk of hypertensive crisis. Allow at least 14 days after discontinuing an MAOI before starting atomoxetine.
Pressor agents: Use caution when combining atomoxetine with vasopressors or other agents that increase blood pressure or heart rate (pseudoephedrine, albuterol). Additive cardiovascular effects may occur.
Antihypertensives: Atomoxetine may reduce the effectiveness of antihypertensive medications due to its pressor effects. Blood pressure should be monitored.
Drugs affecting gastric pH: Atomoxetine absorption is not significantly affected by H2-receptor antagonists or proton pump inhibitors.
Alcohol: While atomoxetine does not potentiate alcohol effects, concurrent use is not recommended due to potential for additive CNS depression and increased cardiovascular effects.
CYP2D6 substrates: Atomoxetine is a substrate but not a significant inhibitor or inducer of CYP2D6, so it is unlikely to affect metabolism of other drugs.
Always review the patient's medication list for potential interactions, particularly with psychiatric medications, cardiovascular agents, and CYP2D6 inhibitors.
Clinical pearls
Onset of action: Unlike stimulants that work within hours, atomoxetine requires 2-4 weeks for full therapeutic effect. Counsel patients and families about this delayed onset to improve adherence.
Non-controlled status: Atomoxetine is not a DEA-scheduled controlled substance, making it an attractive option for patients with substance use history or in situations where stimulant diversion is a concern.
Once-daily dosing: Atomoxetine can be administered once daily (morning or evening) or divided twice daily depending on tolerability and symptom coverage needs. Evening dosing may help with morning ADHD symptoms.
CYP2D6 variability: Consider pharmacogenetic testing or empiric dose reduction in patients experiencing excessive adverse effects, as they may be poor metabolizers.
Stimulant alternative: Atomoxetine is particularly useful in patients with comorbid anxiety (stimulants may worsen anxiety), tic disorders (stimulants may exacerbate tics), or substance use disorders.
Cardiovascular monitoring: Obtain baseline heart rate and blood pressure; monitor periodically during treatment. Atomoxetine should be used cautiously in patients with known cardiac disease.
Suicidality screening: Given the black box warning, establish a monitoring plan with the patient and family, especially in the first few weeks of treatment or after dose changes.
Hepatotoxicity vigilance: Educate patients to report jaundice, dark urine, pruritus, or right upper quadrant pain. Check liver enzymes if hepatotoxicity is suspected.
Exam tip: Atomoxetine is the answer when a question describes an ADHD patient with comorbid tic disorder, substance abuse history, or preference to avoid controlled substances. Remember the black box warning for suicidal ideation in pediatric patients.
ATOM for Atomoxetine: Avoid MAOIs, Tics tolerated (unlike stimulants), Onset delayed (2-4 weeks), Monitor for suicidality.
Practice questions
1. A 9-year-old boy with ADHD and comorbid Tourette syndrome is started on atomoxetine. Four weeks later, his parents report improved attention at school but note that he has become tearful and has expressed thoughts that 'everyone would be better off without him.' Vital signs are normal. What is the most appropriate next step in management?
2. A 32-year-old woman with ADHD is prescribed atomoxetine. She is also taking paroxetine 40 mg daily for generalized anxiety disorder. Two weeks after starting atomoxetine, she develops severe nausea, dizziness, and palpitations. Which of the following best explains her symptoms?
3. A 14-year-old boy with ADHD has been treated with methylphenidate for 3 years with good symptom control. His parents express concern about the long-term use of a controlled substance and inquire about switching to atomoxetine. Which of the following is the most accurate statement regarding this change?
Frequently asked questions
How does atomoxetine work?
Atomoxetine works by selectively inhibiting the presynaptic norepinephrine transporter, increasing norepinephrine levels in the prefrontal cortex. This enhances attention, impulse control, and executive function without directly affecting dopamine in reward pathways, which is why it has minimal abuse potential. Unlike stimulant ADHD medications, atomoxetine does not produce immediate effects and requires 2-4 weeks of continuous use to achieve full therapeutic benefit.
What are the side effects of atomoxetine?
Common side effects include nausea, decreased appetite, dry mouth, insomnia, dizziness, and increased heart rate or blood pressure. Serious adverse effects include a black box warning for suicidal ideation in children and adolescents, rare but severe liver injury, cardiovascular effects (tachycardia, hypertension), growth suppression in pediatric patients, and urinary retention. Patients should be monitored regularly for mood changes, cardiovascular symptoms, and signs of liver dysfunction.
Is atomoxetine a controlled substance?
No, atomoxetine is not a controlled substance. Unlike stimulant ADHD medications such as methylphenidate and amphetamines, atomoxetine is not classified as a DEA-scheduled drug because it has minimal abuse potential. This makes atomoxetine an attractive option for patients with a history of substance use disorder, in situations where stimulant diversion is a concern, or when prescribing regulations for controlled substances pose barriers to treatment access.
Atomoxetine vs methylphenidate — what is the difference?
Atomoxetine is a non-stimulant selective norepinephrine reuptake inhibitor, while methylphenidate is a stimulant that blocks dopamine and norepinephrine reuptake. Methylphenidate works within hours and is a controlled substance with abuse potential; atomoxetine takes 2-4 weeks to work and is not controlled. Atomoxetine is preferred in patients with tics, anxiety, or substance use history, while methylphenidate typically provides more robust symptom control and faster onset. Methylphenidate has a higher risk of insomnia and appetite suppression, whereas atomoxetine carries a black box warning for suicidal ideation.
Can atomoxetine be stopped abruptly?
Yes, atomoxetine can generally be stopped abruptly without a formal taper, as it does not cause a withdrawal syndrome. However, some patients may experience transient rebound of ADHD symptoms such as inattention, hyperactivity, or impulsivity upon discontinuation. If side effects are intolerable or treatment is ineffective, atomoxetine can be discontinued immediately. Clinicians should monitor for return of baseline ADHD symptoms and consider alternative treatment strategies as needed.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06BA09
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.